Connect your AI

PTC Therapeutics PTCT Total Equity

Total Equity at other companies

BioMarin PharmaceuticalsBMRN

$6.21B+7.2%

BridgeBio PharmaBBIO

-$2.28B-38.2%

Arrowhead ResearchARWR

$613.98M-10.1%

United TherapeuticsUTHR

$5.9B-13.3%

ALN

Alnylam PharmaceuticalsALNY

——

BiogenBIIB

——

Other financials

Income statement

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total assets$2.9B+8.0%

Cash flow

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is PTC Therapeutics's total equity?: PTC Therapeutics (PTCT) reported total equity of -$180.47M in Q1 2026.
How has PTC Therapeutics's total equity changed year-over-year?: PTC Therapeutics's total equity increased by 2.9% year-over-year, from -$185.76M to -$180.47M.
What is the long-term trend for PTC Therapeutics's total equity?: Over 5 years (2020 to 2025), PTC Therapeutics's total equity has grown at a -15.7% compound annual growth rate (CAGR), from $481.98M to -$205.31M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.